中西医结合疗法治疗幽门螺杆菌阳性

目的探讨中药、中西医结合疗法治疗幽门螺杆菌(Hp)阳性消化性溃疡的远期疗效。方法将Hp阳性消化性溃疡用中药方剂(益胃片)、西药三联(丽珠得乐加甲硝唑加羟氨苄青霉素)、中西医结合疗法(益胃片加西药组用药)治疗根除Hp后,分别随访3年,共94例,观察Hp和溃疡的复发率,并进行比较。结果西药组Hp和溃疡复发率均为26.67%;中药组Hp复发率为9.38%,溃疡复发率为12.50%;中西医结合组Hp复发率和溃疡的复发率均为6.25%。中西医结合组与西药组比较,差异有显著性意义(P＜0.05)。结论中药方剂益胃片和中西医结合疗法治疗Hp阳性消化性溃疡既有很好的Hp根除率,又有很好的溃疡愈合率,Hp和溃疡的复发率也很低,不失为一种较好的治疗Hp阳性消化性溃疡的有效方法。     

中西医结合疗法治疗幽门螺杆菌阳性消化性溃疡94例

目的探讨中药方剂、中西医结合治疗幽门螺杆菌阳性消化性溃疡的远期疗效.方法经内镜证实的消化性溃疡患者94例,随机分为3组,其中中药组32例,益胃丸10粒,4次/d,服药4wk.西药组30例,服丽珠得乐冲剂110 mg,4次/d,服药4wk;甲硝唑0.4,3次/d,服药10 d;羟氨苄青霉素0.5,3次/d,服药10 d.中西医结合组32例,中药组+西药组用药,疗程亦同.服药结束后1mo,复查内镜,检测Hp及病理变化,Hp根除者列入观察.每3mo～6mo复查内镜,随访3 a.结果中药组溃疡复发率12.50%(4/32),Hp复发率9.38%(3/32),西药组溃疡复发率Hp复发率均为26.27%(8/30),中西医结合组溃疡复发率Hp复发率均为6.25%(2/32).中药组与西药组Hp与溃疡复发率相比无差异(卡方检验,P=0.250),中西医结合组与中药组相比无显著差异(卡方检验,P=0.100),中西医结合组与西药组比较,差异显著(卡方检验,P=0.025).结论中药方剂治疗Hp阳性消化性溃疡与西药三联疗法疗效相似,中西医结合疗法既有很好的Hp根除率,又有很好的溃疡愈合率,Hp和溃疡的复发率也很低,不失为一种较理想的治疗Hp阳性消化性溃疡的有效方法     

中西医结合巩固治疗消化性溃疡和防止复发的效果

目的观察中西医结合巩固治疗消化性溃疡防止复发的效果．方法将内镜确诊近期治愈（溃疡愈合）的消化性溃疡105例，随机分3组，分别应用中西医结合；单独西药；未用药3种不同方法，并进行1a的随访观察．3组在年龄、性别、病程、溃疡直径大小、Hp阳性率、原用药均相近（P＞0．05）．中西医结合组40例，应用丹参20g、公英20g、半枝莲20g、海蛸15g、白芨15g、黄芪15g为主药，1剂／d水煎服，同时每晚加服雷尼替丁300mg．西药组35例，每晚口服雷尼替丁300g．未用药组30例．疗程均为6wk．6mo和1a时复查内镜确诊溃疡是否复发．统计方法：采用组间X2检验结果6mo和1a时，中西医结合组溃疡复发率分别为0％和17．5％（7／40），西药组复发率分别为14．3％（5／35）和62．9％（22／35），未用药组复发率分别为46．7％（14／30）和76．7％（23／30）．中西医结合组溃疡复发率和其他2组比较，差异有非常显著性（P＜0．01）．中西医结合组Hp清除率高于其他2组（P＜0．05）．结论消化性溃疡愈后中西医结合巩固治疗有良好的防止溃疡复发的效果．     

益胃汤联合西药治疗Hp阳性消化性溃疡的临床疗效及对免疫功能的影响

[目的]观察益胃汤联合西药治疗Hp阳性消化性溃疡的临床疗效及对免疫功能的影响。[方法]选择2015年6月~2017年6月我院收治的Hp阳性消化性溃疡患者104例,按照随机数字表法分为观察组(52例)和对照组(52例)。对照组给予西药三联疗法(奥美拉唑、克拉霉素、阿莫西林),观察组在对照组基础上联合中药益胃汤进行治疗,治疗时间均为4周。比较2组患者治疗前后的中医证候积分、胃肠黏膜组织病理改变评分、Hp根除率及临床疗效;检测2组患者相关免疫指标水平的变化;记录2组患者随访期间复发率。[结果]治疗后,观察组患者的中医证候积分、胃肠黏膜组织病理改变评分均明显低于对照组,差异有统计学意义(P0.05)。治疗组Hp根除率、总有效率均明显高于对照组(P0.05)。治疗后,观察组患者免疫指标明显优于对照组(P0.05)。观察组复发率明显低于对照组(P0.05)。[结论]益胃汤联合西药治疗Hp阳性消化性溃疡的临床疗效明显,可改善患者免疫功能,提高溃疡愈合质量,且复发率低,值得在临床上进一步推广使用。     

10天序贯疗法治疗幽门螺杆菌阳性消化性溃疡的疗效分析

幽门螺旋杆菌（Hp）感染是消化性溃疡的重要病因,根除Hp能够治愈消化性溃疡且减少溃疡复发率。Hp根除的经典一线方案根除率逐渐下降。寻找便宜、高效、副作用小的方案十分重要。我们比较了序贯疗法和7天以及14天三联疗法治疗幽门螺杆菌阳性消化性溃疡的疗效,为临床上选择根除Hp方案的提供帮助。     

中西医结合治疗消化性溃疡及预防复发

目的探讨中药锡类散配合西药奥美拉唑、阿莫西林在消化性溃疡疾病中的临床应用价值．方法选经内镜确诊为消化性溃疡患者220例，随机分为中西组（n＝110）和西药组（n＝110），其中合并上消化道出血者98例（44．5％），幽门明显变形狭窄者34例（15．5％），胆汁反流者45例（20．5％）．西药组给予奥美拉唑20mg／d，共4wk，前2wk加服阿莫西林2g／d，4wk疗程结束后3d内复查内镜，同时复查Hp，6mo后再次进行4wk疗程治疗，服药同前．中西组在服西药基础上，加服锡类散，每次1．2g，2次／d，po，4wk后停药，4wk疗程结束后3d内复查内镜，同时复查Hp，6mo后再次进行4wk疗程治疗，服药同前．两组随访1a，观察1a累积各复发例数．结果中西组与西药组溃疡4wk愈合率对比无显著性差异（P＞0．05）．腹痛缓解中西组明显高于西药组，且时间缩短，Hp清除中西组明显好于西药组，年复发率比较：西药组年复发率为53／110（48．1％），中西组年复发率9／110（0．818％），有显著性差异（P＜0．01）．结论中药锡类做配合奥美拉唑，阿莫西林治疗消化性溃疡，能明显抑制Hp生长与繁殖，促进溃疡愈合，并能使溃疡年复发率降至极低水平（复发率＜1％）．     

胃苏冲剂三联疗法治疗消化性溃疡近期及远期疗效

目的观察胃苏冲剂三联疗法治疗消化性溃疡近、远期效果．方法经内镜确诊的53例消化性溃疡患者，其中GU7例，DU46例，男32例，女21例，年龄18岁～72岁．病程6mo～18a．临床表现为痞满36例，上腹疼51例，纳呆26例，嗳气35例，泛酸48例．应用胃苏冲剂（主要由紧苏梗、香附、陈皮、佛手等中药组成）、甲硝唑和羟氢苄青霉素三联治疗，并与对照组32例用麦滋林S颗粒、甲硝唑和羟氢苄青霉素三联疗法进行比较，胃苏冲剂或麦滋林S颗粒均3wk为一疗程，甲硝唑、羟氨苄青霉素均2wk为一疗程．疗程结束后复查内镜和尿素酶法测定Hp．结果经胃苏冲剂三联疗法治疗3wk后，总愈合率治疗组45／53例（81．1％），Hp根除率42／47例（89．3％），Hp根除率2／6（33．3％）；对照组27／32（84．3％），Hp根除者26／28（92．1％），未根除者1／4（25％）．两级总愈合率和Hp根除无明显差异（P＞0．05），两组内Hp根除的愈合率高于未根除者，差异有显著性（P＜0．05），追踪1a，治疗组已愈合43例，7例（16．2％）复发，其中Hp转阳的11例中7例（63．6％）复发，Hp阴性42例中仅5例（11．9％）复发，Hp阳性与阴性组复发率差异显著（P＜0．01），两组溃疡复发率差异不显著（P＞0．05）结论胃苏冲剂三联疗法治疗消化性溃疡有较好的近、远期     

消溃异功散合雷尼替丁治疗消化性溃疡48例疗效观察

采用消溃异功散合雷尼替丁治疗消化性溃疡４８例，并与西药对照组（３２例）比较，结果两组缓解疼痛疗效相近（Ｐ〉０．０５）；溃疡愈合率治疗组为９１．６％，对照组６５．５％；１年复发率治疗组２２．９％，对照组８１．２％；治疗组在缓解其他症状方面亦优于对照组，提示中西医结合疗法是提高消化性溃疡疗效的有效途径之一。     

提高溃疡愈合质量,有效预防复发

根除幽门螺杆菌（Hp）可使溃疡的愈合率提高到95％以上，且愈合时间明显缩短，使复发率也有所降低。但是，并没有得到根本解决。有献报道却根除后消化性溃疡的年复发率为6．5％，却阳性的消化性溃疡年复发率可高达23．33％。     

中西医结合治疗幽门螺杆菌阳性消化性溃疡的临床研究

将幽门螺杆菌（ＨＰ）阳性消化性溃疡６２例随机分为３组，分别用灭幽丸、抗生素三联和中西药联合进行治疗。结果显示，中药组溃疡愈合率为８０．９５％，ＨＰ根除率７６．１９％；西药组溃疡愈合率７５．００％，ＨＰ根除率９０．００％；联合组愈合率９０．４８％，ＨＰ根除率９５．２４％。活动性胃炎消失率中药组和联合组优于西药组。中药组和联合组副作用亦明显少于西药组。     

中西医结合治疗幽门螺杆菌阳性消化性溃疡的临床研究

将幽门螺杆菌（HP）阳性消化性溃疡62例随机分为3组，分别用灭幽丸、抗生素三联和中西药联合进行治疗。结果显示，中药组（灭幽丸）溃疡愈合率为80．95％，HP根除率76.19％；西药组（丽珠得乐＋甲硝唑＋四环素）溃疡愈合率75．00％，HP根除率90．00％；联合组（灭幽丸＋西药组用药）愈合率90．48％，HP根除率95．24％。活动性胃炎消失率中药组（23．80％）和联合组（28．57％）优于西药组（15.00％）。中药组和联合组副作用亦明显少于西药组。     

Endoscopic findings, Helicobacter pylori status, and dyspeptic complaints in vagotomized or medically treated peptic ulcer patients and healthy community controls.

BACKGROUND: The recommendation that Helicobacter pylori be eradicated in surgically treated peptic ulcer patients, regardless of complaints and ongoing ulceration, is controversial. To explore possible endoscopic changes associated with vagotomy and long-term acid suppression, the objectives of this study were to compare the endoscopic findings in the upper gastrointestinal mucosa in relation to H. pylori infection and dyspeptic symptoms in peptic ulcer patients treated surgically or medically. METHODS: Eighty-three randomly selected previously vagotomized peptic ulcer patients, 73 medically treated peptic ulcer patients, and a reference group of 88 healthy community controls underwent an endoscopic investigation. H. pylori infection was determined by culture growth augmented by histology. The endoscopist was blinded for the symptoms and the medical history of all subjects. RESULTS: H. pylori infection was found in 79% of the vagotomized patients, 75% of the medically treated patients, and 70% of the controls. No malignant lesions were found. Active peptic ulceration was the only endoscopic finding associated with abdominal complaints or H. pylori infection. More than half of subjects with normal endoscopy had H. pylori infection. CONCLUSIONS: No differences in endoscopic findings between the surgically and medically treated peptic ulcer patients could be found. The findings do not lend any support to H. pylori infection per se as an indication for eradication therapy in previously vagotomized peptic ulcer patients.     

Endoscopic Findings,Helicobacter pylori Status,and Dyspeptic Complaints in Vagotomized or Medically Treated Peptic Ulcer Patients and Healthy Community Controls

Background: The recommendation that Helicobacter pylori be eradicated in surgically treated peptic ulcer patients, regardless of complaints and ongoing ulceration, is controversial. To explore possible endoscopic changes associated with vagotomy and long-term acid suppression, the objectives of this study were to compare the endoscopic findings in the upper gastrointestinal mucosa in relation to H. pylori infection and dyspeptic symptoms in peptic ulcer patients treated surgically or medically. Methods: Eighty-three randomly selected previously vagotomized peptic ulcer patients, 73 medically treated peptic ulcer patients, and a reference group of 88 healthy community controls underwent an endoscopic investigation. H. pylori infection was determined by culture growth augmented by histology. The endoscopist was blinded for the symptoms and the medical history of all subjects. Results: H. pylori infection was found in 79% of the vagotomized patients, 75% of the medically treated patients, and 70% of the controls. No malignant lesions were found. Active peptic ulceration was the only endoscopic finding associated with abdominal complaints or H. pylori infection. More than half of subjects with normal endoscopy had H. pylori infection. Conclusions: No differences in endoscopic findings between the surgically and medically treated peptic ulcer patients could be found. The findings do not lend any support to H. pylori infection per se as an indication for eradication therapy in previously vagotomized peptic ulcer patients.     

Eradication of Helicobacter pylori improves the healing rate and reduces the relapse rate of nonbleeding ulcers in patients with bleeding peptic ulcer

OBJECTIVE: A causal relationship between Helicobacter pylori (H. pylori) and peptic ulcer complications remains obscure. The aim of this study was to determine the importance of H. pylori and other risk factors for healing rate, ulcer recurrence, and rebleeding in patients with bleeding peptic ulcer. METHOD: A total of 223 patients with H. pylori positive bleeding peptic ulcer were randomly allocated to three treatment groups: 1) quadruple therapy (QT) (88 patients); 2) dual therapy (DT) (88 patients); and 3) omeprazole and placebo therapy (OPl) (47 patients). Endoscopic assessment was performed initially and at 8 and 52 wk. Ulcer healing and eradication rates were assessed; endpoints were ulcer relapse and ulcer rebleeding during 52 wk. RESULTS: Results after 8 and 52 wk were available for 211 and 179 patients, respectively. Eradication rate was 100% (95% CI = 96-100%) in the QT, 84% (95% CI = 74-91%) in the DT, and 4% (95% CI = 1-15%) in the OPl group. Ulcer healing rate was 95% (95% CI = 91-98%) in H. pylori negative and 8% (95% CI = 70-91%) in H. pylori positive patients. Ulcer relapses occurred in 2% (95% CI = 0.5-6%) of H. pylori negative and in 38% (95% CI = 24-54%) of H. pylori positive patients, and rebleeding occurred in five patients (three H. pylori positive and two negative). CONCLUSIONS: Eradication of H. pylori infection enhances healing of bleeding peptic ulcers after endoscopic therapy. H. pylori infection is an important independent risk factor for relapsing of nonbleeding ulcers in patients with bleeding peptic ulcer.     

Peptic ulcer bleeding: interaction between non-steroidal anti-inflammatory drugs, Helicobacter pylori infection, and the ABO blood group system

BACKGROUND: Helicobacter pylori infection is found in almost all patients with an uncomplicated ulcer. Non-steroidal anti-inflammatory drug (NSAID) use is the main risk factor for bleeding peptic ulcer. In the older literature ABO blood groups were mentioned as a risk factor. There is continuing uncertainty about the interaction between these risk factors and the development of peptic ulcer bleeding. We therefore determined the separate and combined effect of NSAIDs, H. pylori infection, and the ABO blood group system in patients with a bleeding peptic ulcer. METHODS: The prevalence of NSAID use, H. pylori infection, and blood group O was determined in 227 patients who were admitted with a bleeding gastric or duodenal ulcer between 1990 and 1997. These results were compared with the expected frequency of these risk factors in the Dutch population. RESULTS: NSAID use was reported in 48.2% of the patients with a bleeding peptic ulcer. The H. pylori prevalence was 62.0%, whereas blood group O was present in 49.3% of the patients. NSAID use was the strongest risk factor for hemorrhage caused by a peptic ulcer (relative risk, 8.4), whereas the relative risk associated with H. pylori infection and blood group O was 1.5 and 1.2, respectively. With univariate analysis NSAID use and H. pylori infection seemed to be separate risk factors and did not really potentiate each other's effect. Moreover, blood group O did not potentiate the strong effect of NSAIDs. CONCLUSION: H. pylori infection may add only a little to the important risk of NSAID use in the development of bleeding peptic ulcers.     

Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients

AIM: One-week triple therapy with proton pump inhibitors, clarithromycin and amoxicillin has recently been proposed as the first-line treatment for Helicobacter pylori (H pylori) infection; however, data regarding the effects of this regimen in China are scarce. The aim of this prospective and randomized study was to compare the efficacy of clarithromycin and metronidazole when they were combined with omeprazole and amoxicillin on eradication of H pylori and ulcer healing in Chinese peptic ulcer patients. METHODS: A total of 103 subjects with Hpylori-positive peptic ulcer were randomly divided into two groups, and accepted triple therapy with omeprazole 20 mg, amoxicillin 1 000 mg and either clarithromycin 500 mg (OAC group, n = 58) or metronidazole 400 mg (0AM group, n - 45). All drugs were given twice daily for 7 d. Patients with active peptic ulcer were treated with omeprazole 20 mg daily for 2-4 wk after anti-H pylori therapy. Six to eight weeks after omeprazole therapy, all patients underwent endoscopies and four biopsies (two from the antrum and two others from the corpus of stomach) were taken for rapid urease test and histological analysis (with modified Giemsa staining) to examine H pylori. Successful eradication was defined as negative results from both examination methods. RESULTS: One hundred patients completed the entire course of therapy and returned for follow-up. The eradication rate of H pylori for the per-protocol analysis was 89.3% (50/56) in OAC group and 84.1% (37/44) in 0AM group. Based on the intention-to-treat analysis, the eradication rate of H pylori was 86.2% (50/58) in OAC group and 82.2% (37/45) in 0AM group. There were no significant differences in eradication rates between the two groups on either analysis. The active ulcer-healing rate was 96.7% (29/30) in OAC group and 100% (21/21) in 0AM group (per-protocol analysis, P>0.05). Six patients in OAC group (10.3%) and five in OAM group (11.1%) reported adverse events (P>0.05). CONCLUSION: One-week triple therapy with omeprazole and amoxicillin in combination with either clarithromycin or metronidazole is effective for the eradication of H pylori. The therapeutic regimen comprising metronidazole with low cost, good compliance and mild adverse events may offer a good choice for the treatment of peptic ulcers associated with H pylori infection in China.     

A comparative study on Helicobacter pylori infection in peptic ulcer disease patients with or without previous eradication therapy

BACKGROUND/AIMS: Although H. pyloric eradication therapy is indicated for peptic ulcer patients, the prevalence of H. pylori infection may be different between patients with active or chronic (scarred) peptic ulcers. This study aimed to compare the prevalence of H. pylori infection in active and chronic peptic ulcer patients with or without previous H. pyloric eradication therapy. METHODOLOGY: Both non-invasive (13C or 14C urea breath test) and invasive methods (rapid urease test and histology) were used to detect H. pylori. From Dec. 2002 to Jan. 2003, 153 patients with 63% male were enrolled in this study. Fifty-six patients who previously received H. pyloric eradication therapy were enrolled as treated patients, and 97 patients who did not receive therapy were enrolled as untreated patients. RESULTS: H. pylori infection rate was still high in untreated patients even when duodenal ulcer had been scarred (96% in active duodenal ulcer and 63% in scarred duodenal ulcer). In treated patients, H. pyloric infected rates were very low when peptic ulcers were scarred (0% in scarred gastric ulcer, 4% in scarred duodenal ulcer and 0% in both scarred ulcers). CONCLUSIONS: H. pyloric eradication therapy is indicated for untreated patients even when endoscopic examination revealed chronic scarred duodenal ulcer.     

Outcome of peptic ulcer bleeding, nonsteroidal anti-inflammatory drug use, and Helicobacter pylori infection.

BACKGROUND & AIMS: NSAIDs and Helicobacter pylori are risk factors for the development of peptic ulcers. A prospective study was conducted to determine prevalence of NSAID use, H pylori infection, and outcome of peptic ulcer bleeding. METHODS: In 2000, data of all 361 patients presenting with peptic ulcer bleeding were prospectively collected in a defined geographical area, including 14 hospitals, and serving a catch area of 1.68 million persons. Follow-up data after a mean of 31 months were obtained from 211 patients. RESULTS: The overall incidence was 21.5 cases per 100,000 persons. Mean age of the group was 70.9 years, 55% were male, and 41% had severe or life-threatening comorbidity. NSAIDs were used by 52%, and in only 17% concomitant acid suppressive therapy was given. H pylori infection was tested in 64%. Of the patients tested for H pylori, 43% were positive. Twenty-three percent were H pylori negative and not using NSAIDs. Rebleeding during initial admission occurred in 19%. Mortality during initial admission was 14%. During follow-up mortality was high, 29%. CONCLUSIONS: Half of all ulcer bleeding was associated with NSAID use. Only a minority of NSAID users used concomitant acid suppressive therapy. H pylori is not assessed systematically in all patients with ulcer bleeding. Almost a quarter of the ulcers were associated with neither H pylori infection nor NSAID use. Mortality, both during hospitalization and follow-up, was substantial.     

北京地区消化性溃疡流行病学分析

目的:了解北京地区消化性溃疡(pepticulcer,PU)的发病特点及变化情况,以及幽门螺杆菌(Helicobacter pylori)与PU的关系,以便为PU的防治工作提供理论依据.方法:研究对象为1999-01-01/12-31在北京29家不同等级医院接受胃镜检查的患者.对其中经内镜下分期诊断为PU活动期及愈合期的患者采用问卷方式进行调查,调查内容主要包括PU患者的性别、年龄、血型、职业、生活习惯、服药情况以及H pylori感染情况.快速尿素酶试验、病理染色、~(13)C-尿素呼气试验和细菌培养检测H pylori感染,其中任一项检测阳性判断为H pylori感染.结果:采用回顾性研究方法,29家医院共有58546例北京地区患者接受了胃镜检查,PU检出率为13.83%.本次调查总共回收调查表3182份,DU:GU为2.81:1.PU检出率以40-60岁患者中检出率(41.2%)最高,GU比DU者平均年龄大6.4岁.不同血型构成比之间有显著性差异(P=0.006),其中以O型血最多,吸烟者明显高于非吸烟者(P=0.012).在1999年有2992例PU患者接受了H pylori感染检测,感染率为54.9%,不同类型PU间H pylori感染率无显著性差异(P=0.72).2042例患者在首次诊断PU时接受了H pylori感染检测,其中1660例(81.3%)H pylori检测阳性.经Logistic回归分析显示PU的复发主要与不规范治疗及H pylori感染密切相关结论:北京地区PU检出率呈下降趋势,患者首次诊断PU时H pylori感染率明显高于自然人群感染率,但1999年度H pylori感染的检出率较低.年龄、O型血、吸烟和H pylori感染是PU发病的危险因素,PU的复发主要与不规范治疗及H pylori感染密切相关.